8-K: Cidara Therapeutics Announces Positive Topline Results from Phase 2b NAVIGATE Trial for CD388 Influenza Prevention

Cidara Therapeutics, Inc. announced positive topline results from its Phase 2b NAVIGATE trial, demonstrating that its investigational drug CD388 significantly prevented seasonal influenza in healthy unvaccinated adults.

Summary

• Cidara Therapeutics' CD388 Phase 2b NAVIGATE trial met its primary endpoint, demonstrating statistically significant prevention efficacy (PE) for seasonal influenza.
• A single dose of CD388 prevented laboratory and clinically confirmed influenza over 24 weeks in healthy unvaccinated adults aged 18 to 64.
• The 450mg dose achieved 76.1% PE (95% CI: 49.3, 89.9; p<0.0001), the 300mg dose achieved 61.3% PE (95% CI: 27.0, 81.2; p=0.0024), and the 150mg dose achieved 57.7% PE (95% CI: 21.1, 78.9; p=0.0050).
• All secondary endpoints were also met with statistical significance, including efficacy at 37.8°C and 37.2°C temperature thresholds, and maintenance of PE up to 28 weeks.
• CD388 was well-tolerated across all doses, with no unexpected dose-limiting treatment-emergent adverse events (TEAEs) or drug-related serious adverse events (SAEs) observed.
• Injection site reaction rates were similar across all CD388 dose groups and placebo.
• The placebo attack rate for the primary endpoint was 2.8% (33 out of 1172 participants).

Sentiment

Score: 9

Explanation: The document reports overwhelmingly positive topline results from a key Phase 2b clinical trial, meeting all primary and secondary endpoints with strong efficacy and a favorable safety profile. This significantly de-risks the program and sets the stage for Phase 3, indicating a very positive outlook for the company's lead candidate.

Positives

• The primary endpoint of Prevention Efficacy (PE) for protocol-defined Influenza-like illness (ILI) events at 24 weeks was met with statistical significance in each of the three dose groups.
• The highest dose (450mg) demonstrated a strong prevention efficacy of 76.1% against symptomatic influenza over 24 weeks.
• All key secondary endpoints, including efficacy at 37.8°C and 37.2°C temperature thresholds, were met with statistical significance at all dose levels.
• CD388 maintained statistically significant prevention efficacy up to 28 weeks.
• The drug was well-tolerated across all doses, with no drug-related serious adverse events observed and no dose-dependent pattern in treatment-emergent adverse events.
• Drug supply for a potential Phase 3 trial is available.

Risks

• Actual results or events could differ materially from forward-looking statements due to various important factors.
• Risks and uncertainties associated with the Company's business and finances in general.
• Risks described under the caption 'Risk Factors' in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 8, 2025, and other future filings with the SEC.
• Cidara's ability to obtain additional financing.
• The success and timing of Cidara's preclinical studies, clinical trials, and other research and development activities.
• Receipt of necessary regulatory approvals for development, as well as changes to applicable regulatory laws in the United States and foreign countries.
• Changes in Cidara's plans to develop its product candidates.
• Cidara's ability to obtain and maintain intellectual property protection for its product candidates.
• The loss of key scientific or management personnel.

Future Outlook

Cidara Therapeutics expects to present additional results from the NAVIGATE trial at upcoming scientific conferences in 2025. The Company has submitted an end of Phase 2 meeting request to the U.S. Food and Drug Administration (FDA) to review the Phase 2b results and further discuss the Phase 3 trial design and start time. The dose for Phase 3 will be selected after full pharmacokinetic (PK) data is assessed, and drug supply is available to begin Phase 3.

Management Comments

• The Company expects to present additional results from the NAVIGATE trial at upcoming scientific conferences in 2025.
• The Company has submitted an end of Phase 2 meeting request to the U.S. Food and Drug Administration (the FDA) to review the Phase 2b results and further discuss the Phase 3 trial design and start time.

Industry Context

The positive results for CD388, a novel Drug-Fc-Conjugate (DFC) designed for influenza prevention, represent a significant development in the infectious disease landscape. If approved, CD388 could offer a new prophylactic option for seasonal influenza, potentially complementing or providing an alternative to traditional vaccines, especially given its extended half-life and single-dose administration. This could be particularly impactful for individuals seeking long-lasting protection or those who do not respond well to vaccines.

Comparison to Industry Standards

• Traditional influenza vaccines typically have varying efficacy rates, often ranging from 40% to 60% in a good year. CD388's 76.1% prevention efficacy at the 450mg dose compares favorably to the average efficacy of many seasonal flu vaccines.
• The extended protection of up to 28 weeks from a single dose is a notable advantage over daily or weekly antiviral regimens and provides longer coverage than a typical flu season.
• Relenza (zanamivir), the active ingredient in CD388, is an FDA-approved neuraminidase inhibitor, but it is typically used for treatment and requires multiple daily doses. CD388's DFC platform enhances its activity and allows for single-dose prophylactic use.
• The safety profile, with no drug-related serious adverse events, is also a positive indicator when compared to the known side effect profiles of various pharmaceutical interventions.

Stakeholder Impact

• Shareholders: Highly positive impact due to successful clinical trial results, which de-risk the lead product candidate and could significantly increase its market value and future revenue potential.
• Patients: Potential for a new, effective, and long-lasting prophylactic option for seasonal influenza, offering an alternative or complement to existing vaccines.
• Employees: Positive impact on morale and job security due to successful product development.
• Regulatory Authorities: Will engage with the FDA for discussions on Phase 3 trial design.

Next Steps

• Present additional full primary analysis details at upcoming scientific conferences in 2025.
• Select the optimal dose for Phase 3 after full pharmacokinetic (PK) data assessment.
• Engage in an End of Phase 2 meeting with the FDA to review results and discuss Phase 3 study design and start time.
• Initiate Phase 3 trial (implied, as drug supply is available and discussions with FDA are planned).

Key Dates

Recommendation

Keywords

Cidara Therapeutics, CDTX, CD388, NAVIGATE trial, Phase 2b, influenza prevention, seasonal flu, antiviral, Drug-Fc-Conjugate, DFC, clinical trial results, biotechnology, pharmaceuticals, infectious disease, FDA meeting, Phase 3